Evidence map›Paper›PMID 42005677›Full record

ArticleHealth science reports2026

A Cross-Sectional Study Shows Emergence of the Delta, 19B, 20A, 20B, 19A, and Omicron Variants of SARS-CoV-2 in Burkina Faso: A Conundrum Within a Conundrum.

Tatiana Doriane Lallogo, Lassina Traore, Ezeckiel B Tibiri, P Abel Sorgho, Prosper Bado, T Edwige Yelemkoure, Pakyendou E Name, Valérie J T E Bazie, Fidèle Tiendrebeogo, H Karim Sombie and 11 more

Abstract read
In one paragraph

Article in Health science reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

21 authors.

Tatiana Doriane LallogoLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Lassina TraoreLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.ORCID https://orcid.org/0000-0003-4719-380X
Ezeckiel B TibiriLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
P Abel SorghoLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Prosper BadoLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
T Edwige YelemkoureLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Pakyendou E NameLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Valérie J T E BazieLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Fidèle TiendrebeogoLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.ORCID https://orcid.org/0000-0002-3619-3268
H Karim SombieLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.ORCID https://orcid.org/0000-0001-6996-8990
Abdoul Karim OuattaraLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.ORCID https://orcid.org/0000-0002-9767-0646
Serge Théophile SoubeigaLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Abdou Azaque ZoureLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.ORCID https://orcid.org/0000-0002-9423-024X
Albert Théophane YonliLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Brice BicabaLaboratoire de Morphologie et organogenèse (LAMO) de l'Université Joseph, KI-ZERBO, Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Rakissida Alfred OuedraogoCentre des Opérations de Réponse aux Urgences Sanitaires (CORUS), Ministère de la Santé Ouagadougou Burkina Faso.
Théodora Mahoukèdè ZohonconLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Florencia Wendkuuni DjigmaLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Assita Lamien/SanouCentre des Opérations de Réponse aux Urgences Sanitaires (CORUS), Ministère de la Santé Ouagadougou Burkina Faso.
Olga M LompoLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.
Jacques SimporeLaboratoire de Biologie Moléculaire et de Génétique (LABIOGENE) Université Joseph KI-ZERBO Ouagadougou Burkina Faso.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Context and Objective: SARS-CoV-2 is an RNA virus that emerged in Wuhan, China. Adaptive mutations in its genome can influence the virus's pathogenicity, enhance its ability to evade the host immune system, and complicate vaccine development. This study aimed to identify the circulating SARS-CoV-2 variants in Burkina Faso and trace their origin. Methodology: Two study populations were included. The first comprised 287 individuals, both asymptomatic and symptomatic, who tested positive for COVID-19. The second consisted of 318 individuals from the general population without clinical symptoms who were tested for serological evidence of SARS-CoV-2 exposure. The study was carried out between January 2021 and December 2022. Sequencing was performed only on the 287 positive samples. Viral RNA was extracted from these clinical specimens, amplified by RT-PCR, and subsequently sequenced. Phylogenetic analysis was conducted using Nextclade v3.8.2 software, with the Wuhan-Hu-1/2019 strain as the reference genome sequence. Results: The identified variants were Omicron (47.91%), Delta (29.41%), 19B (10.92%), 20A (5.88%), 20B (4.20%), and 19A (1.68%). Most of these variants (84.04%) were detected in travelers, and 88.24% were identified from naso-oro-pharyngeal samples. Among the variants, Omicron was the most prevalent and exhibited the highest number of mutations. Complementary serological testing revealed that approximately 22.7% of the general population had been exposed to SARS-CoV-2 during the study period. Conclusion: These findings suggest that multiple introductions of SARS-CoV-2 into Burkina Faso occurred mainly through international travel, with Omicron rapidly becoming dominant. Despite evidence of widespread viral circulation, COVID-19 mortality in Burkina Faso has remained relatively low, according to data from the Ministry of Health. Rather than providing definitive explanations for this paradox, our findings generate hypotheses regarding potential protective factors, including demographic characteristics, host genetics, cross-reactive immunity, and the possibility of underreporting that warrant further investigation guiding responses to future emerging infectious diseases.

Indexed as

Burkina FasoOmicronSARS CoV‐2seroprevalence

Identifiers

PMID42005677
PMCPMC13087621

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.